Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Vickers
    Vickers
  3. Russo
    Russo
  4. Scardino
    Scardino
  5. Eastham
    Eastham
  6. Jarnagin
    Jarnagin
  7. Reuter
    Reuter
  8. D'Angelica
    D'Angelica
  9. Kingham
    Kingham
  10. Ladanyi
    Ladanyi

Groups

  1. Surgery (2075)
  2. Department of Medicine (1355)
  3. Urology (1171)
  4. Solid Tumor Oncology Division (842)
  5. Population Sciences Research Program (830)
  6. Survivorship Research (727)
  7. Epidemiology and Biostatistics (694)
  8. Sloan Kettering Institute Faculty (603)
  9. Department of Pathology and Laboratory Medicine (594)
  10. GSK Faculty (585)
Search Within
Formats
  1. Journal Article (3921)
  2. Meeting Abstract (1056)
  3. Editorial (181)
  4. Review (142)
  5. Correspondence (121)
  6. Guidelines (83)
  7. Research Letter (33)
  8. Conference Paper (27)
  9. Book Section (5)
  10. Miscellaneous (3)
Groups
  1. Surgery (2075)
  2. Department of Medicine (1355)
  3. Urology (1171)
  4. Solid Tumor Oncology Division (842)
  5. Population Sciences Research Program (830)
  6. Survivorship Research (727)

More Groups

People
  1. Harry Herr (271)
  2. Andrew Vickers (229)
  3. Paul Russo (185)
  4. Peter Scardino (173)
  5. James Eastham (163)
  6. William Jarnagin (159)

More People

Years
  1. 2025 (167)
  2. 2024 (255)
  3. 2023 (235)
  4. 2022 (263)
  5. 2021 (233)
  6. 2020 (264)

More Years

Publications
  1. Journal of Urology (768)
  2. European Urology (580)
  3. Lancet Oncology (405)
  4. Urology (392)
  5. Journal of the American College of Surgeons (348)
  6. Journal of Molecular Diagnostics (277)

More Publications

Results (5572)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Spicer, J. D.; Garassino, M. C.; Wakelee, H.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C.; Majem, M.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Antimicrobial use at end of life: A missing link in public health discourse
    Correspondence

    Pandey, S.; Wisniewski, R.; Newman, T.; Seo, S. K.; Rosa, W. E.
    Lancet (2024)

    Fulltext@MSK | Save
  • (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3, randomised, controlled trial
    Journal Article

    Morris, M. J.; Castellano, D.; Herrmann, K.; de Bono, J. S.; Shore, N. D.; Chi, K. N.; Crosby, M.; Piulats, J. M.; FleĢchon, A.; Wei, X. X.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Management of peripheral neuropathy associated with brentuximab vedotin in the frontline treatment of classical Hodgkin lymphoma
    Review

    Abramson, J. S.; Stuver, R.; Herrera, A.; Patterson, E.; Wen, Y. P.; Moskowitz, A.
    Critical Reviews in Oncology/Hematology (2024)

    Fulltext@MSK | Save
  • Sublobar resection for subsolid lung adenocarcinomas: How much margin is enough?
    Editorial

    Rusch, V. W.
    Annals of Thoracic Surgery (2024)

    Fulltext@MSK | Save
  • Leveraging data aggregators to annotate deidentified genomic data derived from commercial laboratory specimens to study COVID-19 severity
    Meeting Abstract

    Dandiker, S.; Latham, A.; Tanpaiboon, P.; Ratajski, A. M.; Bare, L.; Chanock, S.; Fesko, Y. A.; Joseph, V.; Offit, K.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Can multi-cancer early detection screening result in early cancer detection? A modeling study
    Meeting Abstract

    Chhatwal, J.; Xiao, J.; Merdan, S.; El Habr, A.; Tyson, C.; Cao, X.; Raoof, S.; Fendrick, A. M.; Ozbay, A. B.; Limburg, P.; more...
    Value in Health (2024)

    Fulltext@MSK | Save
  • Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor
    Meeting Abstract

    Dai, D.; Tecson, K.; Pan; Ye, X.; Tap, W. D.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Assessment of supporting evidence and postmarketing requirements for therapeutic indications with Real-Time Oncology Drug Review, 2018-2023
    Meeting Abstract

    Mooghali, M.; Mohammad, A.; Wallach, J. D.; Mitchell, A. P.; Ross, J. S.; Ramachandran, R.
    Value in Health (2024)

    Fulltext@MSK | Save
  • Health-related quality of life from a phase 4 global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor (TGCT) previously treated with pexidartinib
    Meeting Abstract

    Desai, J.; Wagner, A. J.; Garcia, I. C.; Cesari, M.; Gordon, M.; Lin, C. C.; Papai, Z.; Ryan, C. W.; Tap, W. D.; Trent, J. C.; more...
    Value in Health (2024)

    Fulltext@MSK | Save